AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23088712 — intervention group
Group type: EXPERIMENTAL
Intervention: More active individuals
Number of subjects: 0
Study 23088712 — intervention group
Group type: COMPARATOR
Intervention: Less active individuals
Number of subjects: 0
Study 22216702 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein
Number of subjects: 52
Study 22216702 — intervention group
Group type: EXPERIMENTAL
Intervention: TAPP
Number of subjects: 52
Study 19695406 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg BID for 15 days
Number of subjects: 23
Study 16332945 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational outreach visits (active group)
Number of subjects: 54
Study 16332945 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational outreach visits during study period)
Number of subjects: 54
Study 15116826 — intervention group
Group type: EXPERIMENTAL
Intervention: Double indicator gloves
Number of subjects: 274
Study 15116826 — intervention group
Group type: COMPARATOR
Intervention: Single surgical gloves
Number of subjects: 274
Study 11132128 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen A (UVB: Octocrylene; UVA: Mexoryl SX, Mexoryl XL, Parsol 1789; TiO2)
Number of subjects: 11
Study 11132128 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen B (UVB: Eusolex 6300, Parsol MCX, Uvinul T150, Neohelipan; UVA: Parsol 1789; TiO2)
Number of subjects: 11
Study 11132128 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen C (Eusolex 6300, Parsol MCX, Uvinul T150; UVA: Parsol 1789; TiO2)
Number of subjects: 11
Study 9447571 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report questionnaires
Number of subjects: 51
Study 9447571 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report questionnaires requiring simple ratings of specified activities
Number of subjects: 51
Study 9447571 — intervention group
Group type: COMPARATOR
Intervention: Actometer (motion-sensing device)
Number of subjects: 51
Study 9447571 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS patients
Number of subjects: 51
Study 9447571 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity levels
Number of subjects: 51
Study 8118643 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonobese obstructive sleep apnea patients and nonobese snorers
Number of subjects: 28
Study 8118643 — intervention group
Group type: COMPARATOR
Intervention: Normal male control subjects
Number of subjects: 28
Study 3310670 — intervention group
Group type: EXPERIMENTAL
Intervention: 250‐mg disulfiram
Number of subjects: 605
Study 3310670 — intervention group
Group type: COMPARATOR
Intervention: 1‐mg disulfiram
Number of subjects: 605
Study 3310670 — intervention group
Group type: COMPARATOR
Intervention: no‐disulfiram
Number of subjects: 605
Study 29553090 — intervention group
Group type: EXPERIMENTAL
Intervention: 2MACE score
Number of subjects: 3172
Study 29553090 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMI‐AF score
Number of subjects: 3172
Study 27256812 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocktail of digoxin (0.25 mg), furosemide (5 mg), metformin (500 mg), and rosuvastatin (10 mg)
Number of subjects: 24
Study 27256812 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocktail of digoxin, furosemide, metformin, and rosuvastatin
Number of subjects: 24
Study 27256812 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased doses of metformin
Number of subjects: 24
Study 27256812 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased doses of furosemide
Number of subjects: 24
Study 25975013 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt supplements (1/8th teaspoon salt, 750 mg) mixed in formula feeds 1 day prior to sweat testing
Number of subjects: 151
Study 25975013 — intervention group
Group type: COMPARATOR
Intervention: No salt supplement (control group)
Number of subjects: 151
Study 24151581 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance of participation in surgical trial
Number of subjects: 166
Study 24151581 — intervention group
Group type: COMPARATOR
Intervention: Refusal of participation in surgical trial
Number of subjects: 166
Study 22031371 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaling rose essential oil
Number of subjects: 43
Study 22031371 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaling ylang-ylang essential oil
Number of subjects: 43
Study 22031371 — intervention group
Group type: COMPARATOR
Intervention: Placebo (rose essence)
Number of subjects: 43
Study 18458605 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil treatment
Number of subjects: 91
Study 18458605 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined MRI and SPECT examination
Number of subjects: 91
Study 16473462 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic applied overtly (expected)
Number of subjects: 0
Study 16473462 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic applied covertly (unexpected)
Number of subjects: 0
Study 16473462 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dose of local anesthetic
Number of subjects: 0
Study 14612001 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab 1 to 1.5 mg/kg on day 1 and day 5 posttransplant
Number of subjects: 34
Study 14612001 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone intraoperatively followed by Neoral monotherapy, with Cellcept for 2-4 months
Number of subjects: 34
Study 10725290 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 659
Study 10725290 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 659
Study 7866928 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan-copolymer pre-brush rinse (0.03% triclosan and 0.125% copolymer)
Number of subjects: 0
Study 7866928 — intervention group
Group type: COMPARATOR
Intervention: Placebo pre-brush rinse
Number of subjects: 0
Study 2158794 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordinary diet plus foods containing refined Konjac meal
Number of subjects: 110
Study 2158794 — intervention group
Group type: COMPARATOR
Intervention: Ordinary diet
Number of subjects: 110
Study 2158794 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined Konjac meal
Number of subjects: 110
Study 7381450 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental condition with superimposed image pairs for 5 minutes
Number of subjects: 89
Study 7381450 — intervention group
Group type: COMPARATOR
Intervention: Control condition with separated image pairs for 5 minutes
Number of subjects: 89
Study 7381450 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental condition with superimposed image pairs for 2 minutes
Number of subjects: 89
Study 7381450 — intervention group
Group type: COMPARATOR
Intervention: Control condition with separated image pairs for 2 minutes
Number of subjects: 89
Study 30817710 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple short-duration sprints (SS)
Number of subjects: 11
Study 30817710 — intervention group
Group type: COMPARATOR
Intervention: Multiple long-duration sprints (LS)
Number of subjects: 11
Study 28708791 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic total mesometrial resection (L-TMMR)
Number of subjects: 213
Study 28708791 — intervention group
Group type: COMPARATOR
Intervention: Nerve-sparing radical hysterectomy (all types)
Number of subjects: 213
Study 26059896 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 3565
Study 26059896 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 3565
Study 23454876 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-mg nicotine lozenge
Number of subjects: 81
Study 23454876 — intervention group
Group type: COMPARATOR
Intervention: Tobacco-free snuff
Number of subjects: 81
Study 21410393 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 89
Study 21410393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 19589891 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive disease management (e.g., infliximab treatment)
Number of subjects: 0
Study 19589891 — intervention group
Group type: COMPARATOR
Intervention: Conservative disease management
Number of subjects: 0
Study 16640927 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix protein (EMP)
Number of subjects: 39
Study 16640927 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (Control)
Number of subjects: 39
Study 16640927 — intervention group
Group type: COMPARATOR
Intervention: Healthy cementum chips (Control)
Number of subjects: 39
Study 12629338 — intervention group
Group type: EXPERIMENTAL
Intervention: Stented group
Number of subjects: 58
Study 12629338 — intervention group
Group type: COMPARATOR
Intervention: Unstented group
Number of subjects: 58
Study 12629338 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 58
Study 10817735 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea
Number of subjects: 100
Study 10817735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 9172985 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep hygiene measures (instructive booklet with 10 recommendations)
Number of subjects: 150
Study 9172985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 9172985 — intervention group
Group type: COMPARATOR
Intervention: Benzodiazepines
Number of subjects: 150
Study 8094001 — intervention group
Group type: EXPERIMENTAL
Intervention: Ditiocarb
Number of subjects: 1333
Study 8094001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1333
Study 3618627 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalline fructose (60 g) supplementation
Number of subjects: 9
Study 3618627 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fructose supplementation)
Number of subjects: 9
Study 29777278 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 195
Study 29777278 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone
Number of subjects: 195
Study 29777278 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet transfusion
Number of subjects: 195
Study 29777278 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in platelet count of 20 × 10^9/L
Number of subjects: 195
Study 27286178 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm water immersion (42°C) for 30 minutes, 3 times per week for 8 weeks
Number of subjects: 18
Study 27286178 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity exercise training (cycling at 70% HRmax) for 30 minutes, 3 times per week for 8 weeks
Number of subjects: 18
Study 24965902 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 15 mg
Number of subjects: 19
Study 24965902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 22698772 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafts performed by residents (n=122)
Number of subjects: 725
Study 22698772 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafts performed by attending surgeons (n=409)
Number of subjects: 725
Study 22698772 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafts performed by residents
Number of subjects: 725
Study 22698772 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafts performed by attending surgeons
Number of subjects: 725
Study 20557145 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ketorolac 31.5 mg
Number of subjects: 321
Study 20557145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 321
Study 18997436 — intervention group
Group type: EXPERIMENTAL
Intervention: TJ‐3022
Number of subjects: 40
Study 18997436 — intervention group
Group type: EXPERIMENTAL
Intervention: TJ‐3023
Number of subjects: 40
Study 16417730 — intervention group
Group type: EXPERIMENTAL
Intervention: CRASH protocol with 3 mg of cetrorelix and stimulation with recombinant human FSH starting on cycle day 2
Number of subjects: 36
Study 16417730 — intervention group
Group type: COMPARATOR
Intervention: Preceding long protocol (control)
Number of subjects: 36
Study 16417730 — intervention group
Group type: EXPERIMENTAL
Intervention: CRASH protocol
Number of subjects: 36
Study 12698130 — intervention group
Group type: EXPERIMENTAL
Intervention: Discectomy
Number of subjects: 20
Study 12698130 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study 12698130 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural control measurement
Number of subjects: 20
Study 10532103 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex therapy including immunotherapy with epithalamin 100 mg, neoadjuvant intraarterial polychemotherapy with 5-fluorouracil 2 g/m2 and cisplatin 100 mg/m2, concurrent radiotherapy, and 4-6 courses of adjuvant polychemotherapy
Number of subjects: 100
Study 10532103 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant polychemotherapy
Number of subjects: 100
Study 10532103 — intervention group
Group type: COMPARATOR
Intervention: Radiation alone
Number of subjects: 100
Study 9479793 — intervention group
Group type: EXPERIMENTAL
Intervention: Instant lottery ticket
Number of subjects: 0
Study 9479793 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lottery ticket)
Number of subjects: 0
Study 1577026 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous rt-PA
Number of subjects: 313
Study 1577026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study 4072875 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibenzoline (130 mg twice daily and 160 mg twice daily)
Number of subjects: 13
Study 4072875 — intervention group
Group type: COMPARATOR
Intervention: Quinidine (300 mg every 6 hours and 400 mg every 6 hours)
Number of subjects: 13
Study 29806663 — intervention group
Group type: EXPERIMENTAL
Intervention: Zygomatic implants
Number of subjects: 71
Study 29806663 — intervention group
Group type: COMPARATOR
Intervention: Augmentation
Number of subjects: 71
Study 24853630 — intervention group
Group type: EXPERIMENTAL
Intervention: Same Task condition
Number of subjects: 2
Study 24853630 — intervention group
Group type: COMPARATOR
Intervention: Different Task condition
Number of subjects: 2
Study 24853630 — intervention group
Group type: EXPERIMENTAL
Intervention: Different Task condition (pre-switch phase)
Number of subjects: 2
Study 24853630 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based paradigm (Experiment 3)
Number of subjects: 2
Study 23050508 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted atazanavir
Number of subjects: 0
Study 23050508 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-sparing atazanavir
Number of subjects: 0
Study 23050508 — intervention group
Group type: EXPERIMENTAL
Intervention: Unboosted atazanavir
Number of subjects: 0
Study 23050508 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir
Number of subjects: 0
Study 20522535 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 50 mg thrice weekly after dialysis
Number of subjects: 53
Study 20522535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 18422595 — intervention group
Group type: COMPARATOR
Intervention: EBM alone
Number of subjects: 25
Study 18422595 — intervention group
Group type: EXPERIMENTAL
Intervention: EBM + Lactodex HMF
Number of subjects: 25
Study 16192582 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (DA)
Number of subjects: 1129
Study 16192582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1129
Study 12799093 — intervention group
Group type: EXPERIMENTAL
Intervention: quinapril
Number of subjects: 134
Study 12799093 — intervention group
Group type: EXPERIMENTAL
Intervention: quinapril + hydrochlorothiazide (HCTZ)
Number of subjects: 134
Study 12799093 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril
Number of subjects: 134
Study 12799093 — intervention group
Group type: COMPARATOR
Intervention: ACE polymorphism (II+ID vs DD)
Number of subjects: 134
Study 10551054 — intervention group
Group type: EXPERIMENTAL
Intervention: Corah's Dental Anxiety Scale (DAS)
Number of subjects: 0
Study 10551054 — intervention group
Group type: EXPERIMENTAL
Intervention: Kleinknecht's Dental Fear Survey (DFS)
Number of subjects: 0
Study 10551054 — intervention group
Group type: EXPERIMENTAL
Intervention: Litt's Oral Surgery Confidence Questionnaire (OSCQ)
Number of subjects: 0
Study 10551054 — intervention group
Group type: EXPERIMENTAL
Intervention: Spielberger's State‐Trait Anxiety Inventory
Number of subjects: 0
Study 10551054 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior experience with tooth extractions
Number of subjects: 0
Study 8688268 — intervention group
Group type: EXPERIMENTAL
Intervention: Portex tracheal tube
Number of subjects: 0
Study 8688268 — intervention group
Group type: COMPARATOR
Intervention: Oxford tube
Number of subjects: 0
Study 1984229 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antibiotic therapy (amoxicillin)
Number of subjects: 136
Study 1984229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 6954863 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin-trace mineral supplement
Number of subjects: 0
Study 6954863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30403366 — intervention group
Group type: EXPERIMENTAL
Intervention: Impella therapy
Number of subjects: 172
Study 30139467 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration plus the AVERT system (n=292)
Number of subjects: 578
Study 30139467 — intervention group
Group type: COMPARATOR
Intervention: Hydration only (n=286)
Number of subjects: 578
Study 27426247 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART intervention group
Number of subjects: 404
Study 27426247 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 404
Study 24976566 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic lifestyle modification (TLM) program, 12-week, 24-session, including individualized health monitoring, group health education, exercise, and calcium-vitamin D supplementation
Number of subjects: 41
Study 24976566 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 41
Study 22588467 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Inspiration Breath-Hold (DIBH)
Number of subjects: 25
Study 20094958 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (mean dosage 55 mg, range: 12.5-150 mg) taken at bedtime following a self-titration protocol.
Number of subjects: 60
Study 18242045 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine and cyclophosphamide
Number of subjects: 0
Study 18242045 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraception and postmenopausal hormone replacement therapy
Number of subjects: 0
Study 18242045 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolic acid
Number of subjects: 0
Study 18242045 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab and other drugs (anti-BAFF, TACI-Fc)
Number of subjects: 0
Study 18242045 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha (type I) inhibition
Number of subjects: 0
Study 18242045 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide vaccination with fragments of autoantibodies or autoantigens
Number of subjects: 0
Study 18242045 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF molecules
Number of subjects: 0
Study 18242045 — intervention group
Group type: EXPERIMENTAL
Intervention: Complement inhibition (anti-C5)
Number of subjects: 0
Study 18242045 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study 18242045 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 0
Study 16033941 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar disease patients
Number of subjects: 18
Study 16033941 — intervention group
Group type: COMPARATOR
Intervention: Control group (subjects without neurologic disease)
Number of subjects: 18
Study 12105254 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent dual silicone catheters (DualKT)
Number of subjects: 42
Study 12105254 — intervention group
Group type: COMPARATOR
Intervention: Arterio-venous vascular accesses (AVA)
Number of subjects: 42
Study 10452624 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vaccine (Haemophilus influenzae type b-tetanus toxoid conjugate vaccine with three-component acellular pertussis vaccine, diphtheria and tetanus toxoids, and inactivated poliovirus vaccine)
Number of subjects: 180
Study 10452624 — intervention group
Group type: COMPARATOR
Intervention: Separate injections (Haemophilus influenzae type b-tetanus toxoid conjugate vaccine and three-component acellular pertussis vaccine, diphtheria and tetanus toxoids, and inactivated poliovirus vaccine)
Number of subjects: 180
Study 10452624 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vaccine
Number of subjects: 180
Study 10452624 — intervention group
Group type: COMPARATOR
Intervention: Separate injections
Number of subjects: 180
Study 8591095 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with additional group work
Number of subjects: 47
Study 8591095 — intervention group
Group type: COMPARATOR
Intervention: Treatment without group work
Number of subjects: 47
Study 8591095 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for mothers
Number of subjects: 47
Study 8591095 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for children
Number of subjects: 47
Study 2669345 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadexomer iodine
Number of subjects: 75
Study 2669345 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (saline wet‐to‐dry compressive dressing)
Number of subjects: 75
Study 29581214 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic pressure <55 mm Hg
Number of subjects: 9093
Study 29581214 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up systolic pressure
Number of subjects: 9093
Study 29581214 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up systolic pressure in intensive arm
Number of subjects: 9093
Study 29228792 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed herbal formulation (Silybum marianum, Urtica dioica, Boswellia serrata) for 90 days
Number of subjects: 60
Study 29228792 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 90 days
Number of subjects: 60